Stroke

A study from Vanderbilt University Medical Center details the apparent risks associated with bleeding and venous thromboembolism following noncardiac surgery.

Results of the phase 3 THALES trial detail the effect of ticagrelor DAPT for reducing the risk of stroke and death in patients with acute ischemic stroke or transient ischemic attack.

An analysis of the REGARDS study is shedding new light on the impact multiple social determinants of health can have on a patient's stroke risk.

Rates of recurrent stroke have been on the decline in recent years—reaching a rate similar to that of non-Hispanic whites by 2013.

Two major organizations have released a new statement outlining topics of research related to VTE in need of further research going forward.

An associate professor of medicine at Yale School of Medicine discusses the results of a study aimed at assessing the potential pathophysiology of COVID-19-associated blood clots.

New data from Mount Sinai Hospital suggests anticoagulant use could improve survival rates among patients hospitalized with COVID-19.

The AAN has released an update to their 2016 practice advisory—changing their stance on PFO closure to reduce risk of second stroke.

The Professor of Medicine at Duke University School of Medicine discusses prescribing DOACs and his opinion on a recent meta-analysis in the Annals of Internal Medicine.

Research from investigators at Brigham and Women's Hospital and Sinai Health is shedding new light on the differences in safety and efficacy between the 2 DOACs.

Analysis of more than 13k patients from Taiwan found a vegetarian diet was linked to a lower risk of incident stroke events later in life.

A fourth-year medical student discusses strategies for anticoagulation reversal in intensive care units from a presentation during the 49th Annual Critical Care Congress in Orlando.

A secondary analysis of patients with prior stroke, TIA, or thromboembolism from AUGUSTUS is revealing more about the use of apixaban in patients with AFib.

A study presented today at the 2020 International Stroke Conference in Los Angeles finds that the long-term use of low-dose aspirin in ischemic stroke patients who have a glucose-6-phosphate dehydrogenase (G6PD) deficiency, may have higher risks of moderate-to-severe bleeding and all-cause death.

The chances of having an acute ischemic stroke (AIS) due to atrial fibrillation 14 days post stroke or transient ischemic attack (TIA) is high, according to a study presented today during the start of the 2020 International Stroke Conference being held in Los Angeles this week.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

In a presentation at AHA, T. Jared Bunch, MD, discusses how early detection of AF could yield positive results down the line for patients.

Results of the TWILIGHT-ACS study revealed use of ticagrelor plus aspirin following coronary intervention in patients with acute coronary syndrome increased the risk of major bleeding.

A new analysis of the Paris Prospective Study III has revealed physical activity at work and physical activity from sport have very different effects on cardiovascular health.

A recent study has found the long-term risk of developing thromboembolism with postoperative atrial fibrillation was similar to that of nonsurgical, nonvalvular atrial fibrillation.

A Q&A with Brett Carroll, MD, director of Vascular Medicine at Beth Israel Deaconess Medical Center, as he discusses stroke management, DOACs, and warfarin.

Investigators from the University of Duke School of Medicine compared results of the PROSPER Study and found results supporting the use of DOACs over warfarin in older patients following ischemic stroke.

An analysis that included data on more than 50,000 patients found that multiple metrics of warfarin control were individuals associated with subsequent bleeding.

Dalteparin sodium injection was shown to result in VTE resolution in a majority of treated patients from a clinical trial.

Patients treated with dabigatran following myocardial injury after noncardiac surgery were 20% less likely to die of a cardiovascular cause.